A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure.

Trial Profile

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Effect of 52 Weeks Treatment With Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms VIVIDD Study
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Aug 2012 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 03 May 2012 Planned end date changed from 1 Jan 2013 to 1 Aug 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top